Reports › Company profiles › Dr Reddy's Laboratories Limited
Dr Reddy's Laboratories Limited
Sector: Pharmaceuticals | HQ: Hyderabad, Telangana | Founded: 1984 | Employees: ~25,800
Listed as: NSE / BSE listed; Nifty 50 constituent; ADR on NYSE | NSE / BSE / NYSE | Ticker: DRREDDY.NS | Website →
Live stock price (NSE)
₹1,280
-14.00 (-1.08%) today
Source: Yahoo Finance · Refreshed every 15 minutes · Fetched 11/5/2026, 4:34:40 pm IST. For information only; not investment advice.
Key people
- K. Satish Reddy (Chairman)
- G. V. Prasad (Co-Chairman and MD)
- Erez Israeli (CEO)
Company overview
Dr Reddy's Laboratories Limited is one of India's largest pharmaceutical companies and a global generics and biosimilars leader. Founded in 1984 by Dr Anji Reddy in Hyderabad, the company is headquartered in Hyderabad and operates 22 manufacturing facilities globally. FY25 consolidated revenue was approximately USD 3.6 billion (₹30,000 crore) with PAT of ₹5,650 crore. The company has a meaningful US generics franchise, an emerging biosimilars portfolio (Reditux, Cresp, Versavo), a strong India domestic branded generics business, and is one of the few Indian pharma companies with an ADR listed on the NYSE.
Business model
Dr Reddy's operates three reporting segments. Global Generics is the largest with US generics, Europe generics, India domestic formulations, and Emerging Markets contributing. The Pharmaceutical Services and Active Ingredients (PSAI) segment is the API and contract manufacturing business serving external customers. The Proprietary Products segment is the smaller specialty branded business with select dermatology and biosimilars launches.
Operating segments
Global Generics, US
US generics franchise. Recent launches include Revlimid (lenalidomide) generic; one of the largest US generics opportunities.
Global Generics, India
India domestic branded generics. Approximately 7 to 8 percent of domestic IPM share.
Global Generics, Europe and Emerging Markets
UK, Germany, Russia, CIS, Latin America, South Africa.
PSAI (API and Contract Manufacturing)
API supply to internal and external customers; strategic backward integration.
Proprietary Products and Biosimilars
Biosimilars portfolio (Reditux rituximab, Cresp darbepoetin, Versavo bevacizumab). Specialty branded launches.
Financial performance and recent trajectory
Dr Reddy's reported FY25 consolidated revenue of approximately ₹30,000 crore with EBITDA of ₹7,200 crore. EBITDA margin in the 23 to 25 percent range reflects the US generics mix and the operating leverage on the India domestic business. The Revlimid generic launch was a meaningful FY24-FY25 revenue and profit driver. R&D spend is approximately 8 to 10 percent of revenue.
Stock performance and shareholder context
Dr Reddy's (NSE: DRREDDY, BSE: 500124, NYSE: RDY) is a Nifty 50 constituent and has an ADR on the NYSE that provides US investor access. The Reddy family holds approximately 26 percent.
12-month price trajectory
Monthly closes over the last 12 months. Source: Yahoo Finance.
Competitive position
In US generics, principal competitors are Teva Pharmaceutical, Sandoz, Sun Pharma, and Aurobindo Pharma. In India domestic, Sun Pharma, Cipla, Mankind Pharma, and Torrent Pharma. In biosimilars, the principal competitors are Biocon, Reliance Life Sciences, Dr Reddy's itself, and global players Pfizer, Samsung Bioepis, Celltrion.
Key risks
US FDA inspection findings; complex-generic and biosimilar development execution; patent expiry timing; INR-USD volatility; India domestic price regulation; emerging markets currency volatility.
Outlook
Strong outlook on the US complex-generics and biosimilars pipeline through FY30. The India domestic business remains the stable base. For new entrants in API manufacturing or generic formulations, Dr Reddy's sets the benchmark for regulatory excellence and capital allocation discipline.
KAMRIT point of view
Building or competing with Dr?
KAMRIT advises promoters, family offices, and global enterprises evaluating greenfield entry into the pharmaceuticals sector. Our Bankable DPR with Cost Model and ROI benchmarks your project economics against the listed-company cost structure of Dr and peers. The Execution Partnership tier covers everything from incorporation through commissioning. A 20-minute scoping call with our partners is free.
Related KAMRIT project reports
These reports use Dr Reddy's Laboratories Limited in benchmarking and competitive analysis sections.
Pharmaceutical Formulations Manufacturing Plant Project Report
Pharma & Healthcare · Market ₹4.5 lakh crore · CAGR 11.8%
API / Bulk Drug Manufacturing Plant Project Report
Pharma & Healthcare · Market ₹2.2 lakh crore · CAGR 13.8%
Disclaimer: This profile is compiled by KAMRIT Financial Services LLP for educational and benchmarking purposes only. It is not investment advice, a recommendation to buy or sell securities, or a solicitation. Stock data is provided by Yahoo Finance and may be delayed by up to 20 minutes. Company financial commentary draws on publicly available filings, exchange disclosures, and KAMRIT industry research. Readers should consult a SEBI-registered investment adviser before making investment decisions. KAMRIT is a financial services and compliance firm, not a SEBI-registered investment adviser.